Advertisement
Singapore markets closed

  • Straits Times Index

    3,176.51
    -11.15 (-0.35%)
     

  • Nikkei

    37,068.35
    -1,011.35 (-2.66%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • FTSE 100

    7,895.85
    +18.80 (+0.24%)
     

  • Bitcoin USD

    64,706.41
    +813.57 (+1.27%)
     

  • CMC Crypto 200

    1,371.97
    +59.35 (+4.52%)
     

  • S&P 500

    4,967.23
    -43.89 (-0.88%)
     

  • Dow

    37,986.40
    +211.02 (+0.56%)
     

  • Nasdaq

    15,282.01
    -319.49 (-2.05%)
     

  • Gold

    2,406.70
    +8.70 (+0.36%)
     

  • Crude Oil

    83.24
    +0.51 (+0.62%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • FTSE Bursa Malaysia

    1,547.57
    +2.81 (+0.18%)
     

  • Jakarta Composite Index

    7,087.32
    -79.50 (-1.11%)
     

  • PSE Index

    6,443.00
    -80.19 (-1.23%)
     

Why Nektar (NKTR) Might Surprise This Earnings Season

Zacks Equity Research
Updated

Investors are always looking for stocks that are poised to beat at earnings season and Nektar Therapeutics NKTR may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Nektar is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for NKTR in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 37 cents per share for NKTR, compared to a broader Zacks Consensus Estimate of a loss of 38 cents per share. This suggests that analysts have very recently bumped up their estimates for NKTR, giving the stock a Zacks Earnings ESP of +1.33% heading into earnings season.

Nektar Therapeutics Price and EPS Surprise

Nektar Therapeutics Price and EPS Surprise | Nektar Therapeutics Quote

ADVERTISEMENT

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that NKTR has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Nektar, and that a beat might be in the cards for the upcoming report.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Nektar Therapeutics (NKTR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research